Cover Image
市場調查報告書

Zealand Pharma A/S - purodakutopaiburain分析

Zealand Pharma A/S - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 219753
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Zealand Pharma A/S - purodakutopaiburain分析 Zealand Pharma A/S - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 37 Pages
簡介

Zealand Pharma A/S 是從事胜肽醫藥品的研究與開發的生物製藥公司,同時也致力於在廣大領域上進行產品開發、研究開發。

本報告提供Zealand Pharma A/S的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,後期階段及中止的計劃等相關資訊。

Zealand Pharma A/S的基本資料

  • Zealand Pharma A/S概要
  • 主要資訊
  • 企業資料

Zealand Pharma A/S:R&D概要

  • 主要的治療範圍

Zealand Pharma A/S:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Zealand Pharma A/S:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Zealand Pharma A/S:藥物簡介

  • danegaptide
  • ZP-2929
  • ZP-4207
  • Synthetic Peptide for Diabetes and Obesity
  • Synthetic Peptides for Undisclosed Indications
  • ZP-3022
  • ZPDI-70
  • ZPGG-23
  • ZPGG-72

Zealand Pharma A/S:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Zealand Pharma A/S:最近的開發平台趨勢

Zealand Pharma A/S:暫停中的計劃

Zealand Pharma A/S:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • rotigaptide

Zealand Pharma A/S:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08031CDB

Summary

Global Markets Direct's, 'Zealand Pharma A/S - Product Pipeline Review - 2016', provides an overview of the Zealand Pharma A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Zealand Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Zealand Pharma A/S
  • The report provides overview of Zealand Pharma A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Zealand Pharma A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Zealand Pharma A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Zealand Pharma A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Zealand Pharma A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Zealand Pharma A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zealand Pharma A/S Snapshot
    • Zealand Pharma A/S Overview
    • Key Information
    • Key Facts
  • Zealand Pharma A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Zealand Pharma A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Zealand Pharma A/S - Pipeline Products Glance
    • Zealand Pharma A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Zealand Pharma A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Zealand Pharma A/S - Drug Profiles
    • ZP-1848
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZP-4207
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZP-2929
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Diabetes and Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Undisclosed Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZP-3022
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPDI-70
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPGG-23
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPGG-72
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPI-98
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zealand Pharma A/S - Pipeline Analysis
    • Zealand Pharma A/S - Pipeline Products by Target
    • Zealand Pharma A/S - Pipeline Products by Route of Administration
    • Zealand Pharma A/S - Pipeline Products by Molecule Type
    • Zealand Pharma A/S - Pipeline Products by Mechanism of Action
  • Zealand Pharma A/S - Recent Pipeline Updates
  • Zealand Pharma A/S - Dormant Projects
  • Zealand Pharma A/S - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zealand Pharma A/S, Key Information
  • Zealand Pharma A/S, Key Facts
  • Zealand Pharma A/S - Pipeline by Indication, 2016
  • Zealand Pharma A/S - Pipeline by Stage of Development, 2016
  • Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016
  • Zealand Pharma A/S - Partnered Products in Pipeline, 2016
  • Zealand Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016
  • Zealand Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Zealand Pharma A/S - Phase II, 2016
  • Zealand Pharma A/S - Phase I, 2016
  • Zealand Pharma A/S - Preclinical, 2016
  • Zealand Pharma A/S - Pipeline by Target, 2016
  • Zealand Pharma A/S - Pipeline by Route of Administration, 2016
  • Zealand Pharma A/S - Pipeline by Molecule Type, 2016
  • Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016
  • Zealand Pharma A/S - Recent Pipeline Updates, 2016
  • Zealand Pharma A/S - Dormant Developmental Projects,2016

List of Figures

  • Zealand Pharma A/S - Pipeline by Indication, 2016
  • Zealand Pharma A/S - Pipeline by Stage of Development, 2016
  • Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016
  • Zealand Pharma A/S - Partnered Products in Pipeline, 2016
  • Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016
  • Zealand Pharma A/S - Pipeline by Target, 2016
  • Zealand Pharma A/S - Pipeline by Route of Administration, 2016
  • Zealand Pharma A/S - Pipeline by Molecule Type, 2016
  • Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016
Back to Top